Engineered Respiratory Syncytial Viruses with Control of Cell-to-Cell Virus Transmission for Enhanced Safety of Live Virus Vaccines
- Summary
- OSU researchers have developed a method to control the rate of cell-to-celltransmission of human RSV, making it possible to tailor vaccines to thestrength each person needs for maximum protection without side effects. The method also allows for the creation of anon-functional RSV which could be used for immunocompromised patients whorequire more stringent safety conditions. The vaccine created from this method would be easy to produce sincethere is no need to for weakened RSV.
- Technology Benefits
- Virus cell to cell transmission can be blocked entirely or fine-tuned to different levels Improved vaccine safety Higher antigen production, recognition, and efficacy Easier production than attenuated viruses Controlled spread of virus without negative side effects
- Technology Application
- Prevention of human RSV outbreaks
- Detailed Technology Description
- None
- *Abstract
-
None
- *Background
- Respiratory Syncytial Virus (RSV) is the largest viral cause ofpediatric bronchiolitis worldwide, a respiratory disease that results in over100,000 deaths per year. RSV can alsocause adult lung diseases such as pneumonia and poses a serious risk for theelderly and the immunocompromised. Unfortunately,a vaccine for RSV is not currently available. Although, live-attenuated (weakened) RSV virus offers the most promisefor a future vaccine, previous and current efforts have failed to produce avaccine that is both effective and safe to use without the risk of severe sideeffects.
- *Stage of Development
- Proof of concept stage.
- Country/Region
- USA
For more information, please click Here
